Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction
Document Type
Article
Publication Date
4-1-2023
Abstract
Fetal growth restriction (FGR) leading to low birth weight (LBW) is a major cause of neonatal morbidity and mortality worldwide. Normal placental development involves a series of highly regulated processes involving a multitude of hormones, transcription factors, and cell lin-eages. Failure to achieve this leads to placental dysfunction and related placental diseases such as pre-clampsia and FGR. Early recognition of at-risk pregnancies is important be-cause careful maternal and fetal surveillance can potentially prevent adverse maternal and perinatal outcomes by judicious pregnancy surveillance and careful timing of birth. Given the association between a variety of circulating maternal biomarkers, adverse pregnancy, and perinatal outcomes, screening tests based on these biomarkers, incorporating mater-nal characteristics, fetal biophysical or circulatory variables have been developed. However, their clinical utility has yet to be proven. Of the current biomarkers, placental growth fac-tor and soluble fms-like tyrosine kinase 1 appear to have the most promise for placental dysfunction and predictive utility for FGR.
Keywords
Circulating biomarkers, Placental dysfunction, Utility, Predicting, Fetal growth restriction
Divisions
obstetrics
Publication Title
Clinical Science
Volume
137
Issue
8
Publisher
Portland Press Ltd
Publisher Location
1ST FLR, 10 QUEEN STREET PLACE, LONDON, ENGLAND